Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KM

Prothena beat adjusted Q2 loss estimates, reaffirmed 2026 cash-use guidance and highlights partner p

Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(0.36) per share which missed the analyst

Prothena (PRTA) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimat

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena reported financial results for the second quar

Shares of Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) passed below its 200-day moving

Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-mark

Crown Holdings Inc (CCK) stock gained 16.4% in pre-market trading after reporting strong Q2 results

Prothena shares climb as late-stage partnered programs advance, milestone payments strengthen financ

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Sarepta Th

https://www.sec.gov/Archives/edgar/data/1559053/000104546326000004/xslF345X06/primary_doc.xml

PRTA posted a Q1 profit as a $50M Novo Nordisk milestone payment boosted revenue and improved its 20

Citizens analyst Jason N. Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperform a

Prothena Corp (NASDAQ:PRTA) reported quarterly earnings of $0.60 per share which beat the analyst co

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena today reported financial results for the first

Prothena Corporation plc (NASDAQ:PRTA) today announced that the U.S. Food and Drug Administration (F

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announces Novo Nordisk obtains Fast Track Desi

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena promoting Ms. Kingston to Chief Strategy Offic

The mean of analysts' price targets for Prothena (PRTA) points to a 120.2% upside in the stock. Whil

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena partners presented clinical data updates for p

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena earned a $50 million milestone from Novo Nordi

Prothena Corporation plc is maintained at a Hold rating due to mixed phase 2 data and long timelines

The consensus price target hints at an 118.1% upside potential for Prothena (PRTA). While empirical

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced its Board has authorized a Share Rep

PRTA posts a narrower year-over-year Q4 loss. Revenues miss estimates, as it outlines 2026 cash burn

RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:PRTA) with a Sector Perform an

Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript

Prothena (PRTA) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimat

Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(0.40) per share which beat the analyst co

Citizens analyst Jason Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperform and

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pi

Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial,

Prothena Corporation plc (NASDAQ:PRTA) announced the publication of Phase 2 clinical trial data for

HC Wainwright & Co. analyst Andrew S. Fein maintains Prothena Corp (NASDAQ:PRTA) with a Buy a

RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:PRTA) with a Sector Perform an

Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(0.68) per share which beat the analyst co

Piper Sandler analyst Yasmeen Rahimi maintains Prothena Corp (NASDAQ:PRTA) with a Overweight and

HC Wainwright & Co. analyst Andrew S. Fein maintains Prothena Corp (NASDAQ:PRTA) with a Buy a

Prothena Corporation plc (NASDAQ:PRTA), announced today that Bristol Myers Squibb communicated in a

JMP Securities analyst Jason Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperfor

The FDA now requires earlier MRI screening for Alzheimer's drug Leqembi to detect ARIA-E, a rare

Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates fo